Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 5/20 | 0.65 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.65 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.65 |
| ▸ | GSK3B | P49841 | 4/20 | 0.65 |
| ▸ | CSNK1G2 | P78368 | 4/20 | 0.65 |
| ▸ | PRKD2 | Q9BZL6 | 4/20 | 0.65 |
| ▸ | CSNK1G1 | Q9HCP0 | 4/20 | 0.65 |
| ▸ | CSNK1G3 | Q9Y6M4 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | GSK3A | P49840 | 3/20 | 0.65 |
| ▸ | TAOK1 | Q7L7X3 | 3/20 | 0.65 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.65 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.65 |
| ▸ | CDK2 | P24941 | 1/20 | 0.65 |
| ▸ | CLK2 | P49760 | 1/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.64 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2746326 | 0.93 | MAPK8 (0.68) | MAPK8MAPK9PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL2745692 | 0.93 | MAPK8 (0.67) | MAPK8MAPK9PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL2745608 | 0.92 | MAPK8 (0.72) | MAPK8MAPK9PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL3477647 | 0.92 | BRAF (0.64) | MAPK8MAPK9PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL2746102 | 0.92 | MAPK8 (0.64) | MAPK8MAPK9PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL2745868 | 0.90 | MAPK8 (0.67) | MAPK8MAPK9PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL13920919 | 0.89 | MAPK8 (0.60) | MAPK8MAPK9PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL2746069 | 0.89 | MAPK8 (0.70) | MAPK8MAPK9PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL2745681 | 0.89 | MAPK8 (0.69) | MAPK8MAPK9PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL2745763 | 0.88 | MAPK8 (0.67) | MAPK8MAPK9PRKD3MAP4K4CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178672-B2 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase | ARQULE, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178672-B2 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase | ARQULE, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2258704-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | ArQule, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090111985-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | ARQULE, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111985-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | ARQULE, INC. | 2009-04-30 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281955-A1 | RAF inhibitors and their uses | BRAF, RAF1, ARAF | MAPK8 301/4885MAPK9 297/4885PRKD3 472/4885 |
| US-20090111985-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | MAPK1, MAPK14, MAPK15 | MAPK8 33/4885MAPK9 39/4885PRKD3 607/4885 |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | BRAF, RAF1, ARAF | MAPK8 298/4885MAPK9 275/4885PRKD3 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.